Furthermore, to be able to target disseminating tumor cells, the author of the study functionalized the particles using specific antibodies to deliver the PLK1-specific CRISPR-Cas9 components to epidermal growth factor receptor (EGFR)-positive tumor cells throughout the animal body, providing a solution to simultaneously target localized and circulating tumors [118]. Here, PLK1 is linked to neoplasm.